NEW YORK – After acquiring Lucira Health in a bankruptcy auction in 2023, Pfizer has decided to shut down the business, a Pfizer spokesperson told GenomeWeb.

In its Q3 2022 filing with the US Securities and Exchange Commission, Lucira noted that some of the delays were the result of a lack of clinical data. The firm at one point had to amend its ...

CAP suggested in a letter to HHS that FDA regulation of LDTs conflicts with President Trump's Jan. 31 executive order instructing agencies to reduce regulations.

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.